Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.

Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease. It differs from other beta-agonists in that it has a very low intrinisic efficacy, especially when compared with the other available long-acting beta-agonist, formoterol. Receptor desensitization and down-regulation has been described with the chronic use of beta-agonists. This effect may not be the same with all beta-agonists and may be related to their stabilization of altered receptor states. The extreme hydrophobicity and high-affinity quasi-irreversible binding of salmeterol have rendered studies examining the mechanisms by which it mediates receptor desensitization, down-regulation, and internalization difficult. We determined the capacity of salmeterol to induce beta(2)AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degradation, and beta-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies. Despite stimulating GRK-mediated phosphorylation of Ser355,356 after 30 min and 18 h to an extent similar to that observed with agonists of high intrinsic efficacy, such as epinephrine and formoterol, salmeterol did not induce significant beta(2)AR internalization or degradation and was incapable of stimulating the translocation of enhanced green fluorescent protein-beta-arrestin2 chimera (EGFP-beta-arrestin2) to the cell surface. Salmeterol-induced receptor endocytosis was rescued, at least in part, by the overexpression of EGFP-beta-arrestin2. Our data indicate that salmeterol binding induces an active receptor state that is unable to recruit beta-arrestin or undergo significant endocytosis or degradation despite stimulating considerable GRK-site phosphorylation. Defects in these components of salmeterol-induced receptor desensitization may be important determinants of its sustained bronchodilation with chronic use.

[1]  A. Burlingame,et al.  Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells. , 2005, Biochemistry.

[2]  Yang Xiang,et al.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.

[3]  T. Kohout,et al.  beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Sadashiva S Karnik,et al.  Multiple Signaling States of G-Protein-Coupled Receptors , 2005, Pharmacological Reviews.

[5]  A M Krumins,et al.  The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. , 1997, Molecular pharmacology.

[6]  Stuart Maudsley,et al.  The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling , 2005, Journal of Pharmacology and Experimental Therapeutics.

[7]  D. Rhodes,et al.  Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. , 1992, Molecular pharmacology.

[8]  R. Lefkowitz,et al.  G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. , 2006, The Journal of biological chemistry.

[9]  B. Dickey,et al.  Long-acting Inhaled β2-Agonists in Asthma Therapy , 1998 .

[10]  N. Barnes,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. , 2004, American journal of respiratory and critical care medicine.

[11]  N. Pearce,et al.  β agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999 .

[12]  A. Sharafkhaneh,et al.  Beta-agonist intrinsic efficacy: measurement and clinical significance. , 2002, American journal of respiratory and critical care medicine.

[13]  Jacqueline Friedman,et al.  Role of the G protein-coupled receptor kinase site serine cluster in beta2-adrenergic receptor internalization, desensitization, and beta-arrestin translocation. , 2006, The Journal of biological chemistry.

[14]  E. Israel,et al.  beta-Adrenergic receptor polymorphisms and response to salmeterol. , 2006, American journal of respiratory and critical care medicine.

[15]  R. Lipchik.  Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences , 2006, Evidence-based medicine.

[16]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[17]  J. Friedman,et al.  Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. , 2004, Molecular pharmacology.

[18]  Xavier Deupi,et al.  Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists* , 2005, Journal of Biological Chemistry.

[19]  R. Clark,et al.  Kinetic analysis of agonist-induced down-regulation of the beta(2)-adrenergic receptor in BEAS-2B cells reveals high- and low-affinity components. , 2000, Molecular pharmacology.

[20]  S. Green,et al.  Human lung cell beta 2-adrenergic receptors desensitize in response to in vivo administered beta-agonist. , 1995, The American journal of physiology.

[21]  Robert H. Moore,et al.  Rab11 regulates the recycling and lysosome targeting of β2-adrenergic receptors , 2004, Journal of Cell Science.

[22]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[23]  D. Cockcroft,et al.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol. , 1995, Chest.

[24]  D. Thiriot,et al.  Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. , 1999, Biochemistry.

[25]  Kristina Lorenz,et al.  Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. , 2005, The Journal of biological chemistry.

[26]  B. J. Knoll,et al.  Agonist-induced sorting of human beta2-adrenergic receptors to lysosomes during downregulation. , 1999, Journal of cell science.

[27]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[28]  J. Friedman,et al.  Desensitization of β2-Adrenergic Receptors with Mutations of the Proposed G Protein-coupled Receptor Kinase Phosphorylation Sites* , 1998, The Journal of Biological Chemistry.

[29]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[30]  A. Seibold,et al.  β2-Adrenergic Receptor Desensitization, Internalization, and Phosphorylation in Response to Full and Partial Agonists* , 1997, The Journal of Biological Chemistry.

[31]  N. Hanania,et al.  The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.

[32]  M. Caron,et al.  Cellular Trafficking of G Protein-coupled Receptor/β-Arrestin Endocytic Complexes* , 1999, The Journal of Biological Chemistry.

[33]  S. Hill,et al.  Characterization of Isoprenaline- and Salmeterol-Stimulated Interactions between β2-Adrenoceptors and β-Arrestin 2 Using β-Galactosidase Complementation in C2C12 Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[34]  M. Caron,et al.  Role of β-Arrestin in Mediating Agonist-Promoted G Protein-Coupled Receptor Internalization , 1996, Science.

[35]  David J. Vaughan,et al.  Role of the G Protein-coupled Receptor Kinase Site Serine Cluster in β2-Adrenergic Receptor Internalization, Desensitization, and β-Arrestin Translocation* , 2006, Journal of Biological Chemistry.

[36]  B. J. Knoll,et al.  Partial agonists and G protein-coupled receptor desensitization. , 1999, Trends in pharmacological sciences.

[37]  V. Gurevich,et al.  The molecular acrobatics of arrestin activation. , 2004, Trends in pharmacological sciences.

[38]  Martin J. Lohse,et al.  β-Arrestin Binding to the β2-Adrenergic Receptor Requires Both Receptor Phosphorylation and Receptor Activation* , 2005, Journal of Biological Chemistry.

[39]  R Barber,et al.  Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. , 1996, Molecular pharmacology.

[40]  Robert J. Lefkowitz,et al.  G-protein-coupled Receptor Kinase Specificity for β-Arrestin Recruitment to the β2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer* , 2006, Journal of Biological Chemistry.

[41]  N. Pearce,et al.  Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999, The Journal of allergy and clinical immunology.

[42]  C. Malbon,et al.  Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Angelides,et al.  Ligand-stimulated beta 2-adrenergic receptor internalization via the constitutive endocytic pathway into rab5-containing endosomes. , 1995, Journal of cell science.

[44]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[45]  Stephen J Hill,et al.  Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells. , 2005, The Journal of pharmacology and experimental therapeutics.

[46]  Vernon M. Chinchilli,et al.  β-Adrenergic Receptor Polymorphisms and Response to Salmeterol , 2006 .

[47]  M. Johnson,et al.  The pharmacology of salmeterol. , 1993, Life sciences.

[48]  J L Benovic,et al.  Role of Clathrin-mediated Endocytosis in Agonist-induced Down-regulation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[49]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[50]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[51]  S. Green,et al.  Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding , 1996, The Journal of Biological Chemistry.

[52]  B. J. Knoll,et al.  Salmeterol‐induced desensitization, internalization and phosphorylation of the human β2‐adrenoceptor , 1998, British journal of pharmacology.